BCMA/CD3 BiTE for RRAL or NDAL Amyloidosis With Insufficient Depth of Hematologic Response After Induction Therapy

Inclusion Criteria: * Male or female patients aged 18 years or older * Biopsy-proven diagnosis of AL amyloidosis, according to the following standard criteria: * Histochemical diagnosis of amyloidosis, as based on tissue specimens with Congo red staining with exhibition of an apple-green birefringence * If clinical and laboratory parameters are insufficient to establish AL amyloidosis, or in cases of doubt, amyloid typing may be necessary * Provide informed consent form * Measurable disease, as defined by serum differential free light-chain concentration (dFLC; defined as the difference between amyloid forming \[involved\] and nonamyloid forming \[uninvolved\] free light-chain \[FLC\]) ≥50 mg/L) * Received at least one prior line of therapy * Must have been exposed to CD38 mAb * Relapsed/refractory AL amyloidosis or newly diagnosed AL amyloidosis with insufficient depth of hematologic response after induction therapy * Relapsed is defined as documented progressive disease \>60 days after the last dose of prior therapy * Refractory is defined as the documented absence of a hematologic response or hematologic progression on or within 60 days after the last dose of prior therapy * Insufficient depth of hematologic response is defined as less than hematological PR by 2 cycles or less than hematologic VGPR by 4 cycles * Eastern Cooperative Oncology Group performance status ≤3 * Clinical laboratory values: * Absolute neutrophil count ≥1000/µL * Platelet count ≥75,000/µL * Hemoglob…